Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind active-controlled study of QLM2010 for prevention of cisplatin-induced nausea and vomiting
CTR20242556Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of QLM2010 in chemotherapy-induced nausea and vomiting (CINV), sponsored by Qilu Pharmaceutical. Started Jul 2024; status: completed.
02
Drugs
QLM2010
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on CTR20242556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242556.